Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient

Inclusion Criteria: * Asthmatic Patient : * Male or Female from 18 to 70 years old, * Diagnosis of asthma confirmed by * Existence of one or more following symptoms over 3 months at least (wheezing dyspnea, wheezing, chronic cough and tightness in the chest…) * AND past pulmonary function test showing a reversible obstructive ventilatory syndrome after inhaled short-acting bronchodilators (improvement of FEV1 above 12% and at least 200 mL FEV1 gain compare to pre-bronchodilatator FEV1) * AND a removal of the clinically suspected differential diagnoses of asthma (vocal cord dysfunction, Churg-Strauss syndrome etc…). The comorbidities should have been explored and treated or on treatment at enrollment. * Subject agreed to participate to the study and the biological samples collection, * Subject is affiliate to a social security system. * Inclusion criteria for severe asthmatic patient : Patient with one of the following criterion will be considered as severe asthmatic patient : * Patient with a controlled asthma but using high dose of inhaled corticosteroids with another therapeutic classes, * OR Patient with uncontrolled asthma despite treatment, * OR Patient with worsening asthma despite treatment. --\>Inclusion criteria for non-severe asthmatic patients : * Moderate Asthmatic patient without standard of care treatment since at least one week before the exploratory visit. --\>Controlled sample: * Non asthmatic cadaveric adults Exclusion Criteria: * Asthmatic Patient : * Underage, * Pregnant or breast-feeding women, * Adult on guardianship * Active smoker (smoked or Inhaled), * former smokers (smoked or Inhaled) with a smoking history of ≥10 pack years since less than 5 years. * Patient with asthma exacerbation the 4 past weeks before the exploratory visit.. * Patient treated by long term oral corticosteroids or ongoing biological therapy or stopped within the 3 months before exploratory visit. * Patient with severe acute or chronic organ disorder (cardiovascular, respiratory, hepatic, renal, malabsorption) * Patient with history of unstable angina, * Patient with platelet count abnormality, or primary or acquired thrombopathy, or an aPTT (activated Partial Thromboplastin Time) greater than or equal to 1,5 times normal or patient with a Quick Time \> 26 seconds * Patient under a systemic immunomodulatory or immunosuppressive treatment * Patient with anticoagulants or anti-platelet aggregating drugs other than D-lysin acetylsalicylate and that could not be suspended before the bronchial fibroscopy. * Patient with hypersensitivity to the treatment used during the bronchial fibroscopy: Hydroxyzine, Midazolam, Xylocaine. * Patient with AME (Government Medical Assistance), * Patient having physical and psychological disabilities to follow the protocol, * Patient included in another interventional research protocol, * Patient having risk factors of Creutzfeld-Jakob disease * Controlled sample: * Asthmatic patient